

AWARD NUMBER: W81XWH-19-1-0625

TITLE: Gut Symbiotic Lipid A Family: Structures and Immunomodulation in IBD

PRINCIPAL INVESTIGATOR: Dennis L. Kasper

CONTRACTING ORGANIZATION: Harvard Medical School

REPORT DATE: OCTOBER 2021

TYPE OF REPORT: ANNUAL

PREPARED FOR: U.S. Army Medical Research and Development Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

*Form Approved*  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

<b>1. REPORT DATE</b> OCTOBER 2021		<b>2. REPORT TYPE</b> ANNUAL		<b>3. DATES COVERED</b> Sep 30,2020-Sep 29,2021	
<b>4. TITLE AND SUBTITLE</b>  Gut Symbiotic Lipid A Family: Structures and Immunomodulation in IBD				<b>5a. CONTRACT NUMBER</b>	
				<b>5b. GRANT NUMBER</b> W81XWH-19-1-0625	
				<b>5c. PROGRAM ELEMENT NUMBER</b>	
<b>6. AUTHOR(S)</b>  Dennis L. Kasper Sungwhan F. Oh  E-Mail: dennis_kasper@hms.harvard.edu				<b>5d. PROJECT NUMBER</b>	
				<b>5e. TASK NUMBER</b>	
				<b>5f. WORK UNIT NUMBER</b>	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b>  President & Fellows of Harvard College 25 Shattuck St, Boston MA 02115				<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b>  U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012				<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>	
				<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>	
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b>  Approved for Public Release; Distribution Unlimited					
<b>13. SUPPLEMENTARY NOTES</b>					
<b>14. ABSTRACT</b> As essential molecules composing the outer membrane of gram-negative bacterial pathogens, glycolipids such as lipopolysaccharides (LPSs) and lipooligosaccharides (LOSs) have been extensively investigated, and their shared lipid A structure has been studied in depth. However, studies of the same family of molecules in commensal bacteria are disproportionately scarce. In fact, the LPS/LOS of commensals such as Bacteroides have been regarded as "inactive" in terms of their ability to stimulate host innate pattern recognition receptors (PRRs) and subsequent downstream responses. Recent studies have challenged this poorly documented view, revealing critical contributions of the LPS/LOS of mucosal commensals to host immune development and disease susceptibility. Indeed, commensal lipid A is synthesized with greater structural diversity and more extensive chemical modification than the lipid A of pathogens. However, only a few scattered reports have elucidated the structure–function relationships of these molecules. We have identified and studied the immunomodulatory capsular polysaccharide A (PSA) of Bacteroides fragilis, a ubiquitous human gut symbiont that signals through Toll-like receptor 2 (TLR2). We have recently found that PSA is covalently attached to a glycolipid anchor (GLA), the structure of which is essentially identical to that of the lipid A of this microbe. Removal of the GLA abrogates the TLR2-mediated immunomodulatory activity of PSA, and much of the innate immune activity of PSA can be recapitulated with the GLA alone. These results led us to hypothesize that structurally diverse lipid A molecules of B. fragilis and related symbiotic bacteria can modulate host immune responses by distinct activation/regulation of PRR-mediated signaling pathways. To address this hypothesis, we propose a multidisciplinary investigation that takes advantage of high-sensitivity and LC-MS/MS platforms; genome-wide, high-throughput metabolomics screening technology; molecular microbiology; in vivo immunology; and gnotobiotic animal studies. All aspects of this work will be developed and expertized by two closely collaborating research groups.					
<b>15. SUBJECT TERMS</b>  NONE LISTED					
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>  Unclassified	<b>18. NUMBER OF PAGES</b>  9	<b>19a. NAME OF RESPONSIBLE PERSON</b> USAMRMC
<b>a. REPORT</b>  Unclassified	<b>b. ABSTRACT</b>  Unclassified	<b>c. THIS PAGE</b>  Unclassified			<b>19b. TELEPHONE NUMBER</b> (include area code)

## 1. Introduction

A diverse community of commensal microbes colonize the intestine and play a crucial role in immune homeostasis by producing a broad range of microbial factors that can modulate immune response of the host. Recent advances in microbiome research have uncovered a complex relationship between symbiotic microbes and the host immune system. The microbiome is indispensable for maintaining immune tolerance while eliciting a proper immune response against pathogen infection. However, there is still a fundamental lack of in-depth insights into the molecular structure of symbiotic molecules responsible for immunomodulatory activity. Among a myriad of commensal microbes inducing various immunomodulatory outcomes, we have studied a human gut symbiotic microbe, *Bacteroides fragilis*, and its outer membrane associated glycolipids, including polysaccharide A (PSA). We previously demonstrated that *B. fragilis* PSA can effectively inhibit the progression of colonic inflammation and autoimmune neuroinflammation by promoting IL-10 from CD4<sup>+</sup> T cells. Our detailed chemical analysis of PSA molecule discovered a glycolipid anchor moiety that is structurally similar, if not identical, to lipid A molecules found as part of the lipooligosaccharides (LOS) of this microorganism. Of significant interest, the removal by acid hydrolysis of this lipid A anchor from *B. fragilis* PSA significantly abolishes IL-10 activity suggesting a functional importance of this glycolipid moiety for PSA-mediated immunomodulation.

Our proposed research under support from DoD CDMRP is to investigate a functional correlation between the molecular structure of *B. fragilis* glycolipid and immunomodulatory activity. From our lipidomic analysis of *B. fragilis* PSA, we discovered that unlike conventional lipid A structures found in *Escherichia coli*, the glycolipid portion of individual molecules of PSA are comprised of structurally distinct lipid A variants with varying degrees of acylation and phosphorylation. During the first-year of this grant, we conducted a groundwork of structure-activity investigation by using a series of chemically synthesized lipid A structural variants that recapitulate the molecular structure of variable lipid A molecules found in *B. fragilis* LOS. We examined the immunomodulatory activity of each synthetic lipid A molecular variants in dendritic cell (DC) culture *in vitro* and tested therapeutic potential of each lipid A variant using *in vivo* disease model. During our second-year of work in this program, we continued our research to delineate underlying mechanisms of how these lipid A variants are recognized and how the immunological landscape in DCs are differentially modulated by lipid A structural variations.

## 2. Keywords


Gut microbiota, Symbiotic microbes, Immunomodulation, Lipid A, Structure-activity relationship, Inflammatory bowel disease

## 3. Accomplishments

Among the proposed aims in our proposal, **Kasper lab** has mainly focused on the tasks described in the Specific Aim 3 and Aim 4.


### Specific Aim 3. To assess the immunomodulatory impact of symbiotic lipid A *in vitro*

Our previous findings revealed a graded pattern of cytokine production that is correlated with chemical structure of lipid A molecular variants with different degrees of acylation (tri- to hexa-acylated) and phosphorylation (mono- or di-phosphorylated). We found that the under-acylated monophosphoryl lipid A (MPLA) weakly induced proinflammatory cytokines (e.g. IL-1 $\beta$ , IL-6, IL-8, IL-12, and TNF- $\alpha$ ) in DCs, while highly inducing expression of co-inhibitory molecules such as PD-L1 and ICOSL. We further tested the immunomodulatory activity of the under-acylated MPLAs, especially 4A (tetra-acylated)-MPLA, which induced the highest PD-L1 expression in DCs compared to other synthetic lipid A variants. We expanded our investigation of the immunomodulatory activity of this particular structural variant in DC-CD4<sup>+</sup> T cell co-cultures. First, we labeled OT-II TCR-transgenic T cells with a cell proliferation dye, CellTrace Violet, and then stimulated them with OVA<sub>323-339</sub> peptide (restricted to MHC class II)-pulsed DC with or without 4A-MPLA. Consistent to our previous findings, 4A-MPLA treatment markedly impaired antigen-induced OT-II T cell proliferation (Figure 1A). We also examined the effect of 4A-MPLA on T helper (T<sub>H</sub>) differentiation. For this experiment, we isolated CD4<sup>+</sup> T cells from the spleen and co-cultured them with splenic DCs under various T<sub>H</sub>-polarizing conditions (T<sub>H</sub>1, T<sub>H</sub>2, T<sub>H</sub>17, and T<sub>H</sub>17) in combination with various cytokines and neutralizing antibodies. Interestingly, 4A-MPLA exhibited a prominent inhibitory effect on T<sub>H</sub>17 differentiation while showing no noticeable effect on other T<sub>H</sub> lineage differentiations (Figure 1B). This result corresponds to our first-year findings from DSS-induced colitis, which shows a therapeutic potential of under-acylated MPLA in preventing colonic inflammation.



**Figure 1.** Immunomodulatory effect of 4A-MPLA on CD4<sup>+</sup> T cell proliferation (A) and T<sub>H</sub>17 differentiation (B)  
\* Numbers shown on histogram indicate the number of cell division starting from 0 (undivided) to 1 (less divided) through 5 (more divided)

To have a better understanding of the immunological impact of lipid A structure on DCs, we performed a comprehensive transcriptomic analysis via RNA-Seq. First, we analyzed the entire transcriptomic data of DC treated with different lipid A structural variants. Of significant interest, principal component analysis of RNA-Seq data reveals that each individual lipid A variant



modulates DC to exhibit unique transcriptomic signatures that are mutually distinguishable (Figure 2). Among various changes in immune transcriptome in DCs, we noticed a unique pattern of transcriptional activation that exclusively responds to the under-acetylated MPLA variants. As shown on the heatmap in Figure 3, we found that 3A- and 4A-MPLA significantly activates interferon (IFN)-stimulated genes (ISG), such as *Oas1*, *Oas2*, *Ifit1*, *Mx2*, and *Irf7*, all functionally associated with type I IFN-mediated immune signature. These results indicate that the

**Figure 3.** DC transcriptomic signature of genes highly upregulated upon treatment of the under-acetylated MPLA structural variants

transcriptomic changes in type I IFN-related signature in DCs.

#### Specific Aim 4. To determine the immunomodulatory function of symbiotic lipid A in gnotobiotic animal models


In our prior annual report, we examined the immunomodulatory activity of synthetic lipid A structural variants in DSS-induced colitis model. We demonstrated that among the MPLA variants we tested, oral administration of 4A-MPLA induces the best protective response against colonic inflammation. To elucidate underlying molecular mechanism of such response, we used transgenic mouse model system (*Itgax-cre* x *Tlr4<sup>fllox/fllox</sup>*) to ablate TLR4 signaling specifically in DCs and examined the immunomodulatory response induced by 4A-MPLA treatment in DSS colitis model. This result demonstrates that DC-mediated TLR4 signaling is indispensable for the immunomodulatory response driven by lipid A variants. Based on this result, we are now testing the immunomodulatory activity of these lipid A variants in gnotobiotic conditions to more clearly examine differential activity driven by lipid A structural variation with no interference from the lipid A molecules produced by existing gut microbiota.

During year 2, **Oh lab** focused on the preparation and functional validation of saccharolipid species from various gut symbionts.

#### Specific Aim 1 (Aim 1a Subtask 3)


We have developed a generalizable method to prepare LPS and LOS from more than 40 strains symbiotic microbiota. Saccharolipids (SLs, which include both LPS and LOS). Purification of SLs from gut and oral symbiont species in the order Bacteroidales, which are reported to have similar lipid A structures, yields various types of polysaccharide structural patterns (Figure 5). Three major types have been characterized: (1) low-molecular-weight bands (lipid A-core oligosaccharides [“rough LPS”] similar to the *E. coli* Nissle strain) identified in *B. fragilis* and *B. thetaiotaomicron*, (2) short ladder-type bands identified in *B. dorei* and *B. vulgatus*, and (3) a medium- or high-molecular-weight ladder (similar to *E. coli* LPS but missing lipooligosaccharide [LOS] or lipid A) identified in the genus *Porphyromonas*. Of considerable interest, along with

Principal component analysis of DC transcriptome




**Figure 2.** Principal component analysis of DC transcriptome data \* 3A- (tri-acetylated); 4A- (tetra-acetylated); 5A- (penta-acetylated); 6A- (hexa-acetylated) \* MPLA (mono-phosphoryl lipid A); DPLA (di-phosphoryl lipid A)

molecular variation in lipid A structure influences the immunomodulatory activity to regulate T cell activation in DC-T cell co-cultures and induces




**Figure 4.** DC-specific ablation of TLR4 signaling abrogates lipid A-driven immune-protective response to DSS-induced colitis \* Tlr4 WT (*Itgax-cre* x *Tlr4<sup>+/+</sup>*) \* Tlr4 cKO (*Itgax-cre* x *Tlr4<sup>fllox/fllox</sup>*)




**Figure 5.** SL profiles of representative GI symbionts. SLs were purified from bacterial pellets and run in 10–20% Tris-tricine gel with zinc counterstaining. *fr*, *Bacteroides fragilis*; *ce*, *B. cellulolyticus*; *th*, *B. thetaiotaomicron*; *do*, *B. dorei*; *vu*, *B. vulgatus*; *pu*, *Porphyromonas ueonis*; *pa*, *P. asaccharolytica*; *as*, *Acidaminococcus intestini* D21; *af*, *Acidaminococcus fermentans canada*; *ec*, *E. coli* Nissle 1917; *b4*, *E. coli* serotype O111:B4.

Bacteroidetes (many *Bacteroides* species and neighboring genera) and Proteobacteria (such as *E. coli*), we have determined that several species of Firmicutes (mostly classified as Negativicutes) produce LPS-type SLs consisting of lipid A and a short O-antigen ladder structure (similar to type 2 SLs).




**Figure 6.** (left) Mass spectrometric analysis of Lipid A structure originated from gut symbiotic species, cultured in rich media or monoclonized with GF host. 'xAyP' refers lipid A species with x fatty acyl chains with y phosphate groups.

**Figure 7.** (bottom) Illustration of lipid A species classes from gut symbionts.



Further lipidomic analysis of the lipid A portion of SLs of gut and oral symbionts has confirmed shared structural components among gut symbiont-derived molecules, such as (1) longer acyl chains, (2) lower degrees of acylation, and (3) less phosphorylated diacylglucosamine (Figure 6-7) than that of *E. coli* lipid A. Many taxonomically related species share common structural components (such as 5A1P lipid A in *Bacteroides*), and there are also individual species-specific lipid A modifications, such as the deoxyheptose-conjugated lipid A (5A1P-dHep, assigned on the basis of a 176-Da difference in molecular mass) identified from *B. fragilis*. We also confirmed lipid A profiles of gut luminal content, originated from *B. fragilis* monoclonized mouse and SPF mice.




**Figure 8.** Lipid A profiles of *B. fragilis* ArnT (arabinylosyltransferase) KO and *B. vulgatus* transgenic strains of PGN1123(3-deacylase).

As expected, lipid A profile of monoclonized mice resembles *B. fragilis* culture. SPF mice, whose major SL-producing species are Bacteroidetes, also has monophosphorylated lipid A as major species.

### Specific aim 2 (Aim 2B subtask 2): Structural modification of lipid A by genetic approaches

We have identified and genetically characterized several genes responsible for lipid A structural modification, such as an *arnT* (arabinosyl transferase) and an *lpxF* (1-phosphate phosphatase) homologs (BF3175 and BF3167, respectively). SLs isolated from individual knockout strains shows higher induction of IL-8 than SLs from wild-type strain, suggesting these genes are critical specific structural moiety (Figure 8). Further mass spectrometric analysis identified clear molecular phenotypes, such as loss of monosaccharide capping in the *DarnT* strain or retention of 4'-phosphate in the *DlpxF* strain (Figure 8). We also have generated and characterized a transgenic strain of *B. vulgatus*, heterologously expressing 3-




**Figure 9.** Classification of saccharolipid activity of gut and oral symbionts, shown as induction of IL-6 from human monocytes. Based on efficacy (EC<sub>50</sub> value), SLs can be clustered in four types.

deacylase of *Porphyromonas gingivalis* (PGN1123); this addition shifts the major lipid A species from pentaacylated to tetraacylated diglucosamine. These results from chemical and genetic studies illustrate the technical feasibility of manipulating target genes of interest in SL biosynthesis and purifying molecules with structural relevance for assessment.

### Specific aim 3 (Aim 3a subtask 1 and 2) : In vitro immunostimulatory actions of gut commensal LOS

Immunostimulatory activities of purified LOS and lipid A has been assessed with human monocytes. Human peripheral blood monocyctic cells (PBMCs) was isolated by Ficoll-gradient centrifugation. Adherent monocytes were isolated and treated with wide range of LOS. Results clearly show that gut symbiont-derived LOS can be classified in four groups by their efficacy (Figure 9): 1) high (EC<sub>50</sub><1ng/mL), 2) intermediate (EC<sub>50</sub> 1~10ng/mL), 3) low (EC<sub>50</sub>>10ng) and 4) inactive. LOS structures largely correlate with efficacy: Most of group 1 LOS resembles typical *E. coli* lipid A (step-ladder pattern with LOS), group 2 shows prominent lipid A and/or LOS, group 3 has short o-antigen ladder pattern and group has 4 long o-antigen ladder pattern.

Quantitative analysis of lipid A content, as well as lipid A pattern by MALDI-TOF/TOF analysis is under way.



**Figure 10.** Activities of LOS purified from genetically manipulated *B. fragilis* strains and a *B. vulgatus* strain with *P. gingivalis* deacylase PGN1123.

We also have generated several *B. fragilis* mutants of lipid A biosynthesis. Several mutants such as DArnT (phosphate capping enzyme), DlpxF (4'-phosphatase) and DBCAT (involved in acyl chain branching) showed higher responses from monocytes (Figure 10).

### **Training and Professional Development**

A postdoctoral trainee **Hyung-Soo Cho, Ph.D.** has been working on the investigation of chemical structure-immunologic activity relationship of lipid A molecules since the beginning of the project. He submitted an abstract to Keystone eSymposia, Harnessing the Microbiome for Disease Prevention and Therapy 2021 Conference, and the abstract was selected for Trainee Scholarship awarded by the conference committee. Also, he was recently invited to present our current work in Korean-American Biomedical Society at University of Massachusetts Medical School and Crohn's and Colitis Foundation Investigators Research Symposium. For our transcriptome data analysis, he has been collaborating with the Biostatistician (Alos Diallo) in our department and learning how to process raw RNA-Seq data and visualize data by creating a heatmap or performing pathway analysis using various software (Morpheus and Cytoscape).

**Ji-Sun Yoo, Ph.D.**, postdoctoral fellow at Oh lab, has been investigating lipid A biosynthesis pathways and functions of gut symbiotic bacteria. Dr. Yoo has been awarded a postdoctoral research fellowship from National Research Foundation of Korea, on "Human antiviral immune responses induced by symbionts".

### **5. Changes/Problems**

1. During our DC transcriptomic analyses, we found transcriptomic activation of ISG signature in DCs responding to the under-acylated MPLA structural variants. These genes are functionally associated with anti-viral immune function mediated by IFN- $\beta$ , which has a dichotomous function based on various immunological contexts. We anticipate that these lipid A structural variants may enhance anti-viral immunity through the activation of type I IFN-associated genes while preventing an excessive immune response of the host. As a proof-of-concept, we will also try to test whether these lipid A variants in a lethal influenza A/PR8 challenge model.

2. Because of pandemic-related facility shutdown and relocation (Mar 2020-Jun 2021), there has been adjustments in the timeline of subaims using MALDI-TOF/TOF instrument. We have mitigated delay in two ways:

1) While preparing for the transposon-based metabolomic screening method set up, we have carried out targeted genetic study and lipid A profiling of KO and transgenic strains. Among various genetically manipulated strains generated, several strains producing one form of lipid A as dominant chemical structure (Figure 4) have been grown in larger scale and LOS prepared for functional validation as well as further purification of lipid A. Examples are: a) *B. fragilis* ArnT KO with pentaacylated-monophosphorylated form and b) *B. vulgatus* transgenic strain with heterologously expressed *P. gingivalis* PGN\_1123.

2) We have adjusted timelines, and changed order of several experiments. We have prepared LOS from up to 25 species and 10 genetically modified strains. *In vitro* assays using purified LOS and lipid A were carried out, while MALDI-TOF/TOF methodology is being established.

### **6. Products**

During year 2, we published one research articles to date which this award partially funded.

**Oh SF†\***, Praveena T\*, Song HB, **Yoo JS**, Jung DJ, Erturk-Hasdemir D, Hwang YS, Lee CC, Le Nours J, Kim HS, Lee J, Blumberg RS, Rossjohn J†, Park SB†, **Kasper DL†**. Host immunomodulatory lipids created by symbionts from dietary amino acids. *Nature*. *In press*. († Co-corresponding authors, \* co-first authors)

### **7. Participants & Other Collaborating Organizations**

Name:	Sungwhan Oh
Project Role:	<i>Principal Investigator</i>
Research Identifier (e.g. ORCID ID):	0000-0002-0280-7903
Nearest person month worked:	3.0
Contribution to Project:	<i>Dr. Oh did three major tasks for the project.</i> 1) <i>Structural analysis of purified lipid A molecules from B. fragilis</i>

	<p>2) <i>supervised genetic and chemical characterization of B. fragilis and other commensal lipid A / LOS structures.</i></p> <p>3) <i>Worked closely with Dr. Kasper planning overall directions.</i></p>
Funding Support:	-

Name:	Jisun Yoo
Project Role:	<i>Research fellow</i>
Researcher Identifier (e.g. ORCID ID):	0000-0003-3100-0794
Nearest person month worked:	6.0
Contribution to Project:	<p><i>Dr. Yoo carried out three major tasks.</i></p> <ol style="list-style-type: none"> <li>1) <i>Genetic characterization of gut commensal lipid A molecules, generating multiple knockout strains of lipid A biosynthesis in B. fragilis and other Bacteroides.</i></li> <li>2) <i>Optimization of in vitro assay system for TLR2/TLR4 response to commensal Lipid A, using transfected cell lines.</i></li> <li>3) <i>Developed a method to isolate LOS molecules from multiple gut commensal strains.</i></li> </ol>
Funding Support:	National Research Foundation of Korea (Sep 2021~)

Name:	Byoungsook Goh
Project Role:	Research fellow
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	4.0
Contribution to Project:	<p><i>Dr. Goh carried out three major tasks.</i></p> <ol style="list-style-type: none"> <li>1) <i>MALDI-TOF/TOF analysis methodology optimization for lipid As</i></li> <li>2) <i>Establishing high-throughput lipidomic screening platform of bacterial transposon library</i></li> </ol>
Funding Support:	

Name:	Eungyo Choi
Project Role:	<i>Research Technician</i>
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	6.0
Contribution to Project:	<i>Dr. Choi contributed to the preparation and isolation of B. fragilis lipid A molecules for further chemical and biological characterizations.</i>
Funding Support:	-

Name:	Dennis Kasper
Project Role:	<i>Principal Investigator</i>
Researcher Identifier (e.g. ORCID ID):	
Nearest person month worked:	1.8
Contribution to Project:	<i>Dr. Kasper supervised this project, organized and planned the execution of specific aims and worked with Dr. Oh on planning chemical and microbiological studies.</i>
Funding Support:	-

Name:	Hyoung-Soo Cho
Project Role:	Research Fellow
Researcher Identifier (e.g. ORCID ID):	0000-0003-0899-8541
Nearest person month worked:	12.0
Contribution to Project:	1) Structure-activity analysis of individual lipid A structural variants <i>in vitro</i> 2) Examination of immunomodulatory activity of lipid A structural variants in the steady-state condition and DSS-induced colitis model <i>in vivo</i>
Funding Support:	Crohn's and Colitis Foundation Research Fellows Award